업계의 PD-1xVEGF와 PD-L1xVEGF 이중 특이성 항체 : 비즈니스, 파이프라인, 경쟁 분석

PD-1 x VEGF and PD-L1 x VEGF Bispecific Antibodies: A Business, Pipeline and Competitor Analysis from an Industry Perspective

EUR 2,000 ￦ 3,296,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

EUR 4,000 ￦ 6,592,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

EUR 6,000 ￦ 9,888,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

동급 최초이자 현재까지 동급 최고인 PD-1xVEGF 이중 특이성 항체인 Ivonescimab은 항 PD-1 Pembrolizumab(Keytruda)와 비교하여 우수한 임상 프로파일과 라이선스 계약의 경제 조건에 따라 파이프라인에서 경쟁 기준을 설정했습니다. PD-1과 VEGF("협조성")를 한 분자로 동시에 저해함으로써 항PD-(L)1요법과 항VEGF요법을 따로 병용하는 경우와 비교하여 안전성 프로파일이 개선되어 항종양 활성이 증강될 수 있습니다. 세 번째 특이성을 가진 차세대 삼특이성 PD-(L)xVEGF 항체는 임상적 이익을 더욱 향상시킬 수 있습니다. 파이프라인에 있는 PD-(L)1xVEGF 항체 개발 후보의 거의 모두는 중국에서의 개발에 중점을 두는 중국의 바이오 테크놀로지 기업으로부터 태어나고 있습니다. 이것은 유럽과 미국의 바이오 의약품 기업에게 세계 개발 및 마케팅에서 전략적 제휴 기회를 제공하는 것입니다.

본 보고서에서는 PD-1 x VEGF와 PD-L1 x VEGF 이중 특이성 항체에 대해 조사 분석하고, 이해관계자, 연구개발 파이프라인, 임상 프로파일, 신약 후보의 분자 구조, 비즈니스 거래에 관한 2025년 2월 현재의 업계 정세를 해설 및 분석했습니다.

보고서에서 다루는 기업

목차

제품 설명

자주 발생하는 약어

제1장 주요 요약

제2장 소개

제3장 PD-(L)1xVEGF 이중특이성과 삼중특이성 파이프라인 분석

• 이중특이성 PD-1xVEGF(R) 항체의 파이프라인
• 이중특이성 PD-L1xVEGF 항체의 파이프라인
• 삼중특이성 PD-L1xVEGF 항체의 파이프라인

제4장 PD-(L)1xVEGF 이중 특이성 항체의 임상 경험

• PD-1xVEGF 항체
  • Ivonescimab
  • MHB039A
• PD-L1xVEGF 항체
  • HB0025
  • IMM2510
  • PM8002/BNT327

제5장 PD-(L)1xVEGF(R) 이중 특이성 항체와 삼중특이성 항체의 약제 프로파일

• PD-1xVEGF(R) 이중 특이성 항체의 약제 프로파일
  • AI-081
  • CR-001
  • Ivonescimab
  • Jankistomig
  • JS207
  • LM-299
  • MHB0039A
  • NY-500
  • RC148
  • SCTB14
  • SSGJ-707
• PD-L1xVEGF 이중 특이성 항체의 약제 프로파일
  • AP505, B1962
  • BB-203
  • HB0025
  • IMM2510, SYN-2510
  • PM8002, BNT327
  • SG1408
• PD-(L1)xVEGF 삼중특이성 항체의 약제 프로파일
  • CS2009
  • DR30206
  • GB268
  • HC010
  • OGB2350

제6장 경쟁과 이해관계자 분석

• 첨단 개발에서 PD-(L)1xVEGF 항체의 이해관계자
• 조기 임상 개발에서 PD-(L)1xVEGF 항체의 이해관계자
• 비임상 연구 개발에 있어서의 PD-(L) 1xVEGF(R) 항체의 이해관계자

제7장 PD-(L)1xVEGF 항체를 취급하는 기업의 프로파일

• 3SBio
• Akeso Biopharma
• AP Biosciences
• BioNTech
• Biotheus
• Bright Biologics
• Crescent Biopharma
• CStone Pharmaceuticals
• Genor Biopharma
• Hanzhou Sumgen Biotech
• HC Biopharma
• ImmuneOnco Biopharmaceuticals
• Instil Bio
• LaNova Medicines
• Merck & Co
• Minghui Pharmaceutical Co.
• NAYA Biosciences
• OncoC4
• OneGen Biotechnology
• Ottimo Pharma
• RemeGen
• Shanghai Huaota Biopharmaceutical
• Shanghai Junshi Biosciences
• SinoCellTech Group
• Summit Therapeutics
• Tasly Pharmaceutical
• Zhejiang Doer Biopharma

제8장 PD-1/PD-L1 면역종양 항체 시장

• 시장 개요
• PD-1 항체 시장
• PD-L1 항체 시장
• 이중특이성 PD-1xCTLA-4 및 PD-1xLAG-3 항체 시장
• 판매 정보가 없는 기타 PD-(L1) 항체

제9장 비즈니스 거래: 스핀오프, 자금 조달, 라이선싱, 합병 및 인수, 밸류에이션

• 스핀오프
• 라이선싱
• 합병 및 인수
• 밸류에이션

제10장 참고문헌

SHW

영문 목차

영문목차

This report provides you with a landscape description and analysis of PD-1 x VEGF and PD-L1 x VEGF bispecific antibodies regarding stakeholders, R&D pipeline, clinical profile and molecular structure of drug candidates and business deals from an industry perspective as of February 2025. The first-in-class and so far best-in-class PD-1xVEGF bispecific antibody ivonescimab has set the bar for competitors in the pipeline for a superior clinical profile compared with anti-PD-1 pembrolizumab (Keytruda) and for economic terms of the licensing agreement. The simultaneous blockade of PD-1 and VEGF ("cooperativity") by one molecule may produce enhanced antitumor activity with an improved safety profile compared with the co-administration of separate anti-PD-(L)1 and anti-VEGF therapies. A next generation of trispecific PD-(L)xVEGF antibodies with a third specificity may even further improve the clinical benefit. Nearly all of the PD-(L)1xVEGF antibody development candidates in the pipeline originate from Chinese biotechnology companies with focus on development in China. This provides an opportunity for Western biopharmaceutical companies for strategic collaborations in global development and marketing.

The report brings you up-to-date with information about and analysis of:

• R&D pipeline of bispecific and trispecific PD-1xVEGF(R) and PD-L1xVEGF antibodies;
• Molecular structure of PD-(L)1xVEGF(R) antibodies in development;
• Preclinical and clinical profile of PD-(L)1xVEGF(R) antibodies;
• Cancer indications in early development and in global development;
• Clinical experience with PD-(L)1xVEGF antibodies;
• Background profile of stakeholders (originator and licensee companies);
• Competitor analysis;
• Established market size for PD-1 and PD-L1 checkpoint inhibitor antibodies;
• Business deals with economic terms: spin-offs, financing, licensing; mergers & acquisitions, company valuation.

In preclinical studies, anti-vascular endothelial growth factor (VEGF) and anti-PD-(L)1 antibodies were found to have synergistic antitumor activity. Anti-VEGF not only inhibits angiogenesis but also increases immune effector cell trafficking and infiltration into the tumor microenvironment, allowing for an immuno-responsive environment, which leads to enhanced efficacy of anti-PD-(L)1 inhibitors. Combining anti-PD-(L)1 antibodies with antiangiogenic agents was found to have antitumor activity and tolerable safety in advanced solid tumors. Clinical studies have shown that the combination of PD-(L)1 and VEGF antibodies significantly improves clinical benefit over PD-(L)1 antibody alone in certain settings.

To combine both targeting approaches, bispecific antibodies targeting PD-1 and VEGF by one molecule have been designed and preclinical studies showed that the combination in one molecule was superior to the combination of two separate molecules in antitumor activity.

As PD-1 and VEGF co-express in the tumor microenvironment, the dual-target design of a bispecific antibody combines PD-1 and VEGF to enable the enrichment and retention of macromolecular drugs in the tumor microenvironment, leading to a reduced distribution in the peripheral blood and a decreased toxicity caused by off-target effects.

Methodology:

This report evaluates the industry landscape of PD-1xVEGF(R) and PD-L1xVEGF bispecific and trispecific antibodies in research and development. The report provides a comprehensive overview of the R&D and partnering activities of pharmaceutical and technology companies in the field of PD-(L)1xVEGF(R) antibodies. This report is based on the identification and description of corporate stakeholders including biopharmaceutical companies and biotechnology companies. All publicly available information is fully referenced, either with scientific references (abstracts, posters, presentations, full paper) or hyperlinks leading to the source of information, such as press releases, corporate presentations, annual reports, SEC disclosures and homepage content.

Who will benefit from the report?

• Business development and licensing (BDL) specialists;
• Venture capital, private equity and investment managers;
• Managers of Big Pharma venture capital firms;
• Financial analysts;
• CEO, COO and managing directors;
• Corporate strategy analysts and managers;
• Chief Technology Officer;
• R&D Portfolio, Technology and Strategy Management;
• Clinical and preclinical development specialists.

Companies Mentioned in the Report:

Table of Contents

Product Description

Table of Contents

Frequent Abbreviations

1. Executive Summary

2. Introduction

3. Analysis of PD-(L)1xVEGF bispecific and trispecific pipeline

• 3.1. Pipeline of bispecific PD-1xVEGF(R) antibodies
• 3.2. Pipeline of bispecific PD-L1xVEGF antibodies
• 3.3. Pipeline of trispecific PD-L1xVEGF antibodies

4. Clinical Experience with PD-(L)1xVEGF Bispecific Antibodies

• 4.1. PD-1xVEGF Antibodies
  • 4.1.1. Ivonescimab
  • 4.1.2. MHB039A
• 4.2. PD-L1xVEGF Antibodies
  • 4.2.1. HB0025
  • 4.2.2. IMM2510
  • 4.2.3. PM8002/BNT327

5. PD-(L)1xVEGF(R) Bi- and Trispecific Antibody Drug Profiles

• 5.1. PD-1xVEGF(R) Bispecific Antibody Drug Profiles
  • 5.1.1. AI-081
  • 5.1.2. CR-001
  • 5.1.3. Ivonescimab
  • 5.1.4. Jankistomig
  • 5.1.5. JS207
  • 5.1.6. LM-299
  • 5.1.7. MHB0039A
  • 5.1.8. NY-500
  • 5.1.9. RC148
  • 5.1.10. SCTB14
  • 5.1.11. SSGJ-707
• 5.2. PD-L1xVEGF Bispecific Antibody Drug Profiles
  • 5.2.1. AP505; B1962
  • 5.2.2. BB-203
  • 5.2.3. HB0025
  • 5.2.4. IMM2510; SYN-2510
  • 5.2.5. PM8002; BNT327
  • 5.2.6. SG1408
• 5.3. PD-(L1)xVEGF Trispecific Antibody Drug Profiles
  • 5.3.1. CS2009
  • 5.3.2. DR30206
  • 5.3.3. GB268
  • 5.3.4. HC010
  • 5.3.5. OGB2350

6. Competitor and Stakeholder Analysis

• 6.1. Stakeholders with PD-(L)1xVEGF antibodies in advanced development
• 6.2. Stakeholders with PD-(L)1xVEGF antibodies in early clinical development
• 6.3. Stakeholders with PD-(L)1xVEGF(R) antibodies in non-clinical R&D

7. Profiles of Companies with PD-(L)1xVEGF Antibodies

• 7.1 3SBio
• 7.2. Akeso Biopharma
• 7.3. AP Biosciences
• 7.4. BioNTech
• 7.5. Biotheus
• 7.6. Bright Biologics
• 7.7. Crescent Biopharma
• 7.8. CStone Pharmaceuticals
• 7.9. Genor Biopharma
• 7.10. Hanzhou Sumgen Biotech
• 7.11. HC Biopharma
• 7.12. ImmuneOnco Biopharmaceuticals
• 7.13. Instil Bio
• 7.14. LaNova Medicines
• 7.15. Merck & Co
• 7.16. Minghui Pharmaceutical Co.
• 7.17. NAYA Biosciences
• 7.18. OncoC4
• 7.19. OneGen Biotechnology
• 7.20. Ottimo Pharma
• 7.21. RemeGen
• 7.22. Shanghai Huaota Biopharmaceutical
• 7.23. Shanghai Junshi Biosciences
• 7.24. SinoCellTech Group
• 7.25. Summit Therapeutics
• 7.26. Tasly Pharmaceutical
• 7.27. Zhejiang Doer Biopharma

8. PD-1 and PD-L1 Immuno-Oncology Antibody Markets

• 8.1. Market Overview
• 8.2. PD-1 Antibody Market
• 8.3. PD-L1 Antibody Market
• 8.4. Bispecific PD-1xCTLA-4 and PD-1xLAG-3 Antibody Market
• 8.5. Other PD-(L1) Antibodies without Information on Sales

9. Business Deals: spin-offs, financing, licensing, mergers & acquisitions, valuations

• 9.1. Spin-offs
• 9.2. Licensing
• 9.3. Mergers & Acquisitions
• 9.4. Valuation

10. References

Tables in the Report:

• Table 1: Overview of PD-(L)1xVEGF(R) bi- and trispecific antibodies in the pipeline
• Table 2: Overview bispecific PD-1 x VEGF(R2) antibodies
• Table 3: Overview of structural features of PD-1xVEGF(R) antibodies
• Table 4: Overview bispecific PD-L1 x VEGF antibodies
• Table 5: Overview of structural features of PD-L1xVEGF antibodies
• Table 6: Overview of trispecific PD-(L)1xVEGF antibodies
• Table 7: Overview of structural features of PD-(L)1xVEGF trispecific antibodies
• Table 8: Overview of major efficacy results in clinical phase II studies of ivonescimab
• Table 9: Clinical indications of ivonescimab in phase III studies
• Table 10: Overview of clinical studies with PM8002
• Table 11: Overview of stakeholders with PD-(L)1xVEGF antibodies in advanced development
• Table 12: Overview of Stakeholders with PD-(L)1xVEGF antibodies in early clinical development
• Table 13: Overview of Stakeholders with PD-(L)1xVEGF antibodies in non-clinical R&D
• Table 14: 2023 Total Sales of PD-1 & PD-L1 Antibodies per Class
• Table 15: Sales & Growth Rates of PD-1 & PD-L1 Antibodies 2014-2023
• Table 16: 2023 Individual Sales of Monospecific PD-1 Antibodies
• Table 17: 2023 Individual Sales of Monospecific PD-L1 Antibodies
• Table 18: 2023 Individual Sales of PD-L1 Antibody Combination Regimen
• Table 19: 2023 Individual Sales of Bispecific or Combination PD-1 Antibodies
• Table 20: Approved / Marketed PD-1 & PD-L1 Antibodies without Information on Sales
• Table 21: Overview of business deals related to PD-(L)1 x VEGF(R) targeted bi- and trispecific antibody constructs
• Table 22: Terms of Licensing Deals for PD-(L)1 x VEGF bispecific antibodies

관련자료